APCCC 2022 | Local and systemic therapies for cN1 prostate cancer

Darren Poon, MBChB, FRCR, FHKCR, FHKAM, The Chinese University of Hong Kong, Hong Kong discusses how clinically node-positive (cN1) prostate cancer is currently managed. Dr Poon describes how androgen deprivation therapy (ADT) alone is not adequate for the treatment of cN1 prostate cancer and discusses the importance of both local treatment and systemic therapy (in particular abiraterone) for the treatment of the cN1 prostate cancer subgroup to improve oncological outcomes. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.